Skip to content


Empliciti (elotuzumab) is an antibody pharmaceutical. Elotuzumab was first approved as Empliciti on 2015-11-30. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against SLAM family member 7.
Trade Name Empliciti
Common Name Elotuzumab
Indication multiple myeloma
Drug Class Monoclonal antibodies: humanized, tumors as target
Get full access now